Search research articles
Contact Us
Filters
Showing results (81-90 of 89) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 89 results.
The Journal of Headache and Pain
|
March 26, 2011
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine
Marco Bartolini, Maria Adele Giamberardino, Carlo Lisotto, et al.
The Journal of Headache and Pain
|
May 18, 2012
Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study
Marco Bartolini, Maria Adelaide Giamberardino, Carlo Lisotto, et al.
Sleep Medicine
|
March 22, 2024
Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study
Giovanna Viticchi, Vincenzo Di Stefano, Claudia Altamura, et al.
Frontiers in Bioengineering and Biotechnology
|
March 19, 2021
The Surfactin-Like Lipopeptides From <i>Bacillus</i> spp.: Natural Biodiversity and Synthetic Biology for a Broader Application Range
Ariane Théatre, Carolina Cano-Prieto, Marco Bartolini, et al.
Journal of Neurology
|
January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
The Journal of Headache and Pain
|
September 12, 2018
Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire
Alberto Raggi, Venusia Covelli, Erika Guastafierro, et al.
Neurology and Therapy
|
June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
Piero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Journal of Neurology
|
May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain
|
October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 89) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 89 results.
The Journal of Headache and Pain
|
March 26, 2011
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine
Marco Bartolini, Maria Adele Giamberardino, Carlo Lisotto, et al.
The Journal of Headache and Pain
|
May 18, 2012
Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study
Marco Bartolini, Maria Adelaide Giamberardino, Carlo Lisotto, et al.
Sleep Medicine
|
March 22, 2024
Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter study
Giovanna Viticchi, Vincenzo Di Stefano, Claudia Altamura, et al.
Frontiers in Bioengineering and Biotechnology
|
March 19, 2021
The Surfactin-Like Lipopeptides From <i>Bacillus</i> spp.: Natural Biodiversity and Synthetic Biology for a Broader Application Range
Ariane Théatre, Carolina Cano-Prieto, Marco Bartolini, et al.
Journal of Neurology
|
January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
The Journal of Headache and Pain
|
September 12, 2018
Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire
Alberto Raggi, Venusia Covelli, Erika Guastafierro, et al.
Neurology and Therapy
|
June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
Piero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
Journal of Neurology
|
May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain
|
October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Page
of 9